Program P2 was significantly depleted from AML with CBFB::MYH11 fusion (q < 0.05), which is mainly associated with good survival [33]; significantly depleted from low-risk AML, and significantly enriched in AML with standard risk (Fig. 2B). The gene discussed is MYH11; the disease is acute myeloid leukemia.